ET206 / Expression Therap - LARVOL DELTA

Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells. (PubMed, Front Immunol) - "To better understand the migration of these cells and possibly influence their migration, NSG mice were conditioned with agents to clear BM cellular compartments, i.e., busulfan or total body irradiation (TBI), or promote T-cell migration to inflamed BM, i.e., incomplete Freund's adjuvant (IFA), prior to administering γδ T cells...Using an established neuroblastoma NSG mouse model, we show that intratumorally-injected γMSCs increase the homing of γδ T cells to this tumor. These studies provide insight into the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells in NSG mice, which is critical to understanding the fundamental properties of these cells."

Journal • Preclinical • CNS Tumor • Hematological Malignancies • Neuroblastoma • Oncology • Solid Tumor • CCL2 • CCR2 • IFNG

Initiating a Phase I Gamma Delta T Cell Trial for Neuroblastoma and Strategies to Enhance Anti-Neuroblastoma Effectiveness by Genetic Engineering (IO-SUMMIT EUROPE 2023) - P1 | "Neuroblastoma (NB) is the most common cancer in infants and represents approximately 15% of cancer-related deaths. We initiated a Phase I study using allogeneic ex vivo expanded gamma delta (?d) T cells for relapsed NB (NCT05400603), and have extended the ?d T cell platform to include proprietary cell-specific transgene expression vector designs and gene transfer systems for eBite expression, which generate our Allogeneic Donor Expanded and Programmed T (ADEPT) cells."

New P1 trial • P1 data • CNS Tumor • Gene Therapies • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor